ArticleCancer discovery2021
Open access · greenAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
21.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- The role of neo-adjuvant therapy in cholangiocarcinoma: A systematic review.Frontiers in oncology · 2022Pooled it
- Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.Nature medicine · 2024Trial
- Overexpression of FGFR2 in Mandibular Ameloblastoma Is Potentially Associated with Gene Amplification and Deletion.International journal of molecular sciences · 2026Article
- MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.Nature genetics · 2026Article
- Research on Targeted Therapy for Malignant Tumors of the Biliary Tract.OncoTargets and therapy · 2026Review
- Fibroblast Growth Factor Receptor (FGFR) Inhibitors for the Treatment of Cholangiocarcinoma: Key Therapeutic Developments and Knowledge Gaps.Drug design, development and therapy · 2026Review
- Pharmacological induction of acetyl-CoA carboxylase 1 autophagic degradation attenuates lipid accumulation and cholangiocarcinoma progression.Journal of experimental & clinical cancer research : CR · 2025Article
- FGFR2 fusion/rearrangement analysis in intrahepatic cholangiocarcinoma using DNA/RNA-based NGS and FISH.Virchows Archiv : an international journal of pathology · 2025Article
- Distinct phenotypic consequences of cholangiocarcinoma-associated FGFR2 alterations depend on biliary epithelial cell state.bioRxiv : the preprint server for biology · 2025Article
- Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets.Cancer discovery · 2025Article
- Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model-Based Prediction.JCO precision oncology · 2025Article
- Identification of potent biparatopic antibodies targeting FGFR2 fusion-driven cholangiocarcinoma.The Journal of clinical investigation · 2025Article
- Cholangiocarcinoma Targeted Therapies: Mechanisms of Action and Resistance.The American journal of pathology · 2025Review
- DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming.Cancer discovery · 2025Article
- Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer.NPJ precision oncology · 2024Article
- Tumor-associated characteristics and immune dysregulation in nasopharyngeal carcinoma under the regulation of m7G-related tumor microenvironment cells.World journal of surgical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 6 institutions in 2 countries.
James M Cleary *Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Srivatsan Raghavan *Dana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5374-9918
Qibiao Wu *Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Yvonne Y LiDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Liam F SpurrDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Hersh V GuptaDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5136-6403
Douglas A RubinsonDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5337-5231
Isobel J FetterMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-6021-2713
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-6475-8345
Jonathan A NowakDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Giulia SiravegnaMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Lipika GoyalMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Lei ShiMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Lauren K BraisDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Maureen LoftusDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Atul B ShinagareDana-Farber Brigham and Women's Cancer Center, Department of Radiology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-0273-7359
Thomas A AbramsDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-3101-1573
Thomas E ClancyDana-Farber Brigham and Women's Cancer Center, Department of Surgical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Jiping WangDana-Farber Brigham and Women's Cancer Center, Department of Surgical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Anuj K PatelDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Franck BrichoryDebiopharm International SA, Lausanne, Switzerland.
Anne Vaslin ChessexDebiopharm International SA, Lausanne, Switzerland.
Ryan J SullivanMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-5344-6645
Rachel B KellerDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-6138-9257
Sarah DenningDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Emma R HillDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Geoffrey I ShapiroDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3331-4095
Anna Pokorska-BocciDebiopharm International SA, Lausanne, Switzerland.
Claudio ZannaDebiopharm International SA, Lausanne, Switzerland.
Kimmie NgDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Deborah SchragDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Pasi A JänneDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
William C HahnDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-2840-9791
Andrew D CherniackDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Ryan B CorcoranMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.
Matthew MeyersonDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Antoine DainaSIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.
Vincent ZoeteSIB Swiss Institute of Bioinformatics, Molecular Modeling Group, Lausanne, Switzerland.
Nabeel BardeesyMassachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. Brian_Wolpin@dfci.harvard.edu Bardeesy.Nabeel@mgh.harvard.edu.
Brian M WolpinDana-Farber Brigham and Women's Cancer Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. Brian_Wolpin@dfci.harvard.edu Bardeesy.Nabeel@mgh.harvard.edu.
Dana-Farber Cancer Institute · USMassachusetts General Hospital · USDebiopharm (Switzerland) · CHSIB Swiss Institute of Bioinformatics · CHBrigham and Women's Hospital · USBroad Institute · US
Funding
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MProject 2U54CA224068 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CORCORAN, RYAN BRUCE, FLAHERTY, KEITH T · 2017 to 2021
$6.3MNCI NIH HHS P50 CA127003NCI NIH HHS U54 CA224068
Abstract
We conducted next-generation DNA sequencing on 335 biliary tract cancers and characterized the genomic landscape by anatomic site within the biliary tree. In addition to frequent
Indexed as
AdolescentAdultAgedAged, 80 and overBile Duct NeoplasmsCholangiocarcinomaFemaleHumansMaleMiddle AgedMolecular Targeted TherapyProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2Young AdultFGFR2 protein, humanProtein Kinase InhibitorsReceptor, Fibroblast Growth Factor, Type 2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.